Four OICR-funded studies are exploring transformative approaches in cancer care, leveraging existing research and patient contributions to advance cancer detection, diagnosis, and treatment. These studies, collectively known as the CATALYST program, are designed to maximize the impact of available data and patient samples, pushing the boundaries of clinical practice.
One study, led by Dr. Neil Fleshner, investigates the potential of a common diabetes medication, metformin, to slow the progression of clonal hematopoiesis, a condition linked to an increased risk of blood cancers. Building on previous research, this study aims to further explore metformin's effectiveness through genetic testing, offering a promising avenue for cancer prevention.
Another project, led by Dr. Hon Leong and Dr. Lillian Siu, focuses on developing a blood test to predict treatment response to immunotherapy. The study builds on earlier findings that patients with high levels of endogenous retrotransposable elements (ERE) in their tumors respond better to immune checkpoint inhibitors. By analyzing the same patient samples, the researchers aim to determine if measuring EREs in blood can also predict treatment outcomes.
Dr. Enrique Sanz Garcia and Dr. Scott Bratman are working on a blood test to identify patients at high risk of head and neck cancer recurrence. This study leverages advanced genomic sequencing technology to detect tiny fragments of tumor DNA in blood samples, offering a non-invasive method to assess cancer recurrence risk.
Lastly, Dr. Vikas Gupta and Dr. James Kennedy are developing a system to predict treatment responses in patients with rare blood cancer, myelofibrosis. By reanalyzing existing data, they aim to identify patients suitable for bone marrow transplants and determine the optimal timing for such interventions.
These studies, funded by the Ontario Institute for Cancer Research (OICR), demonstrate the power of reanalyzing existing data and patient contributions. As Dr. Lincoln Stein, OICR's Acting Scientific Director, notes, these projects maximize research efficiency and bridge the gap between scientific discoveries and clinical practice. The CATALYST program, supported by the Ontario government, underscores the commitment to driving life-saving cancer research and improving patient outcomes.
